ReNeuron Group (ReNeuron Group) Debt-to-Asset : 0.05 (As of Sep. 2023)

View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Debt-to-Asset?

ReNeuron Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.19 Mil. ReNeuron Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.23 Mil. ReNeuron Group's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $7.95 Mil. ReNeuron Group's debt to asset for the quarter that ended in Sep. 2023 was 0.05.

ReNeuron Group Debt-to-Asset Historical Data

The historical data trend for ReNeuron Group's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Debt-to-Asset Chart

ReNeuron Group Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.04

0.03

0.04

ReNeuron Group Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.03	0.04	0.04	0.05

Competitive Comparison of ReNeuron Group's Debt-to-Asset

For the Biotechnology subindustry, ReNeuron Group's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ReNeuron Group's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Debt-to-Asset falls into.

ReNeuron Group Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ReNeuron Group's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.186	+	0.325)	/	11.705
	=	0.04

ReNeuron Group's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.193	+	0.234)	/	7.949
	=	0.05

ReNeuron Group (OTCPK:RNUGF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ReNeuron Group Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (ReNeuron Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

RENE.GB:UK RENE:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.